HopeStage
Back to all studies
CompletedNCT00227305

Quetiapine for adolescents with schizophrenia or bipolarity

About this title

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

Read the official source — NCT00227305
Medication studyAges 10–17Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 10 years to 17 years.

Listed locations
Dothan and 47 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2004
Recruitment status
Completed
Enrollment listed in the registry
381
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, India, Malaysia, ...
Age range
From 10 Years to 17 Years
Official registry ID
NCT00227305
Official title
Show the full official title

A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Dothan, United States · Scottsdale, United States · Cerritos, United States

46 more locations
  • Riverside, United States
  • Sacramento, United States
  • San Diego, United States
  • Denver, United States
  • Altamonte Springs, United States
  • Jacksonville, United States
  • Miami, United States
  • Chicago, United States
  • Oak Brook, United States
  • Newton, United States
  • Overland Park, United States
  • New Orleans, United States
  • Las Vegas, United States
  • Rochester, United States
  • Cincinnati, United States
  • Cleveland, United States
  • Lyndhurst, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Memphis, United States
  • Austin, United States
  • Houston, United States
  • San Antonio, United States
  • Richmond, United States
  • Virginia Beach, United States
  • Bellevue, United States
  • Kirkland, United States
  • Milwaukee, United States
  • Lucknow, India
  • Kuala Lumpur, Malaysia
  • Petaling Jaya, Malaysia
  • Davao City, Philippines
  • Mandaluyong, Philippines
  • Manila, Philippines
  • Quezon City, Philippines
  • Poznan, Poland
  • Torun, Poland
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Pretoria, South Africa
  • Kharkiv, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including quetiapine fumarate.

Who was this study for?

Listed age limits: 10 years to 17 years.

Want to explore more studies?

Explore studies